Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) approved as front-line therapy for patients with advanced non-small cell lung cancer (NSCLC) whose tumors harbor activating EGFR mutations [1]. Here, EGFR is linked to non-small cell lung carcinoma.